Graphite Bio clears HSR waiting period for merger with Lenz Therapeutics on Dec. 21

LENZ Therapeutics, Inc.

HSR waiting period under Hart-Scott-Rodino Act expired at 11:59 p.m. ET on December 21, 2023.
Merger with Lenz Therapeutics, previously announced Nov. 14, 2023, remains subject to stockholder approval and other conditions.
Closing will result in Lenz becoming a wholly owned subsidiary of Graphite; combined company intends to list on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.